drugset
drugset / Trial / NCT02085135

A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)

NCT02085135 ↗

Phase 3 Completed 66 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.

Timeline

Start
2014-02
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ALKS 5461 Unknown — Other

Indications

major depressive disorder